CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation

British Journal of Pharmacology

Volumn 168, Issue 4, 2013, Pages 835-849

  Sala, Mariaelvina ^a,b   Braida, Daniela ^b   Pucci, Luca ^a,b   Manfredi, Irene ^c   Marks, Michael J ^d   Wageman, Charles R ^d   Grady, Sharon R ^d   Loi, Barbara ^a   Fucile, Sergio ^c,e   Fasoli, Francesca ^a   Zoli, Michele ^f   Tasso, Bruno ^g   Sparatore, Fabio ^g   Clementi, Francesco ^a,b   Gotti, Cecilia ^a,b  

^a CNR   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS NEUROMED   (Italy)

^d UNIVERSITY OF COLORADO   (United States)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

Author keywords

4 2 and 6 2 nicotinic Ach receptor subtypes; 5 hydroxytryptamine3 receptors; conditioned place preference; neurotransmitter release; partial agonist; rat; self Administration

Indexed keywords

1,2 BIS N CYSTISINYLETHANE; BUNGAROTOXIN RECEPTOR; CYTISINE; DOPAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA3BETA4; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR ALPHA6BETA2; SEROTONIN 3 RECEPTOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VARENICLINE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; ELECTROPHYSIOLOGY; HETEROLOGOUS EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MALE; MOTOR PERFORMANCE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR UPREGULATION; REINFORCEMENT; SMOKING CESSATION; STRIATE CORTEX; TOBACCO DEPENDENCE;

ALKALOIDS; ANIMALS; AZOCINES; BEHAVIOR, ANIMAL; DRUG PARTIAL AGONISM; MALE; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; MOTOR ACTIVITY; NICOTINE; NICOTINIC AGONISTS; PROTEIN BINDING; QUINOLIZINES; RATS; RATS, WISTAR; RECEPTORS, NICOTINIC; SELF ADMINISTRATION; TOBACCO USE CESSATION; TOBACCO USE DISORDER;

EID: 84872896597     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02204.x     Document Type: Article

References (60)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Azam L, McIntosh JM, (2006). Characterization of nicotinic acetylcholine receptors that modulate nicotine-evoked [3H]norepinephrine release from mouse hippocampal synaptosomes. Mol Pharmacol 70: 967-976.
3. Biala G, Staniak N, Budzynska B, (2010). Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats. Naunyn Schmiedebergs Arch Pharmacol 381: 361-370.
4. Bolchi C, Gotti C, Binda M, Fumagalli L, Pucci L, Pistillo F, et al. (2011). Unichiral 2-(2-pyrrolidinyl)-1,4-benzodioxanes: the 2R,2S diastereomer of the N-methyl-7-hydroxy analogue is a potent alpha4beta2- and alpha6beta2-nicotinic acetylcholine receptor partial agonist. J Med Chem 54: 7588-7601.
5. Braida D, Virag W, Ottonello F, Inghilterra S, Gori E, Sala M, (1998). A novel method for self-Administering addicting drugs intracerebroventricularly in a free-choice procedure. Brain Res Brain Res Protoc 3: 135-141.
6. Braida D, Pozzi M, Cavallini R, Sala M, (2001). Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience 104: 923-926.
7. Braida D, Pozzi M, Cavallini R, Sala M, (2002). 3,4 Methylenedioxymethamphetamine (ecstasy) impairs eight-Arm radial maze performance and arm entry pattern in rats. Behav Neurosci 116: 298-304.
8. Braida D, Iosue S, Pegorini S, Sala M, (2004). Delta9- tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-Administration in rats. Eur J Pharmacol 506: 63-69.
9. Braida D, Limonta V, Capurro V, Fadda P, Rubino T, Mascia P, et al. (2008). Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol Psychiatry 63: 286-292.
10. Cahill K, Stead LF, Lancaster T, (2011). Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev (2): CD006103.
11. Canu Boido C, Sparatore F, (1999). Synthesis and preliminary pharmacological evaluation of some cytisine derivatives. Farmaco 54: 438-451.
12. Canu Boido C, Tasso B, Boido V, Sparatore F, (2003). Cytisine derivatives as ligands for neuronal nicotine receptors and with various pharmacological activities. Farmaco 58: 265-277.
13. Carbonnelle E, Sparatore F, Canu-Boido C, Salvagno C, Baldani-Guerra B, Terstappen G, et al. (2003). Nitrogen substitution modifies the activity of cytisine on neuronal nicotinic receptor subtypes. Eur J Pharmacol 471: 85-96.
14. Changeux JP, (2010). Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat Rev Neurosci 11: 389-401.
15. Chatterjee S, Steensland P, Simms JA, Holgate J, Coe JW, Hurst RS, et al. (2011). Partial agonists of the alpha3beta4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. Neuropsychopharmacology 36: 603-615.
16. Chavez-Noriega LE, Crona JH, Washburn MS, Urrutia A, Elliott KJ, Johnson EC, (1997). Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J Pharmacol Exp Ther 280: 346-356.
17. 3H]-dopamine release. Br J Pharmacol 117: 595-606.
18. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. (2005). Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48: 3474-3477.
19. Dallanoce C, Magrone P, Matera C, Frigerio F, Grazioso G, De Amici M, et al. (2011). Design, synthesis, and pharmacological characterization of novel spirocyclic quinuclidinyl-Delta2-isoxazoline derivatives as potent and selective agonists of alpha7 nicotinic acetylcholine receptors. ChemMedChem 6: 889-903.
20. Dani JA, Bertrand D, (2007). Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47: 699-729.
21. 3B subunit is a major determinant of serotonin-receptor function. Nature 397: 359-363.
22. De Biasi M, Dani JA, (2011). Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci 34: 105-130.
23. Etter JF, Stapleton JA, (2006). Nicotine replacement therapy for long-term smoking cessation: a meta-Analysis. Tob Control 15: 280-285.
24. Foulds J, (2006). The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract 60: 571-576.
25. Fowler CD, Kenny PJ, (2011). Intravenous nicotine self-Administration and cue-induced reinstatement in mice: effects of nicotine dose, rate of drug infusion and prior instrumental training. Neuropharmacology 61: 687-698.
26. Freedman R, (2007). Exacerbation of schizophrenia by varenicline. Am J Psychiatry 164: 1269.
27. Fucile S, Renzi M, Lax P, Eusebi F, (2003). Fractional Ca(2+) current through human neuronal alpha7 nicotinic acetylcholine receptors. Cell Calcium 34: 205-209.
28. Fucile S, Sucapane A, Grassi F, Eusebi F, Engel AG, (2006). The human adult subtype ACh receptor channel has high Ca2+ permeability and predisposes to endplate Ca2+ overloading. J Physiol 573 (Pt 1): 35-43.
29. Gotti C, Zoli M, Clementi F, (2006). Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 27: 482-491.
30. Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, Manfredi I, et al. (2009). Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 78: 703-711.
31. Grady SR, Meinerz NM, Cao J, Reynolds AM, Picciotto MR, Changeux JP, et al. (2001). Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum. J Neurochem 76: 258-268.
32. Grady SR, Moretti M, Zoli M, Marks MJ, Zanardi A, Pucci L, et al. (2009). Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release. J Neurosci 29: 2272-2282.
33. Kota D, Sanjakdar S, Marks MJ, Khabour O, Alzoubi K, Damaj MI, (2011). Exploring behavioral and molecular mechanisms of nicotine reward in adolescent mice. Biochem Pharmacol 82: 1008-1014.
34. Lax P, Fucile S, Eusebi F, (2002). Ca(2+) permeability of human heteromeric nAChRs expressed by transfection in human cells. Cell Calcium 32: 53-58.
35. Livingstone PD, Wonnacott S, (2009). Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem Pharmacol 78: 744-755.
36. Luetje CW, Patrick J, (1991). Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J Neurosci 11: 837-845.
37. Lummis SC, Thompson AJ, Bencherif M, Lester HA, (2011). Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor. J Pharmacol Exp Ther 339: 125-131.
38. McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, et al. (2009). Varenicline reduces alcohol self-Administration in heavy-drinking smokers. Biol Psychiatry 66: 185-190.
39. Marks MJ, Whiteaker P, Calcaterra J, Stitzel JA, Bullock AE, Grady SR, et al. (1999). Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the beta2 subunit. J Pharmacol Exp Ther 289: 1090-1103.
40. Marks MJ, Meinerz NM, Brown RW, Collins AC, (2010). 86Rb+ efflux mediated by alpha4beta2-nicotinic acetylcholine receptors with high and low-sensitivity to stimulation by acetylcholine display similar agonist-induced desensitization. Biochem Pharmacol 80: 1238-1251.
41. Mihalak KB, Carroll FI, Luetje CW, (2006). Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70: 801-805.
42. Mineur YS, Picciotto MR, (2010). Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 31: 580-586.
43. Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S, (2011). Suicidal behavior and depression in smoking cessation treatments. PLoS ONE 6: e27016.
44. Museo E, Wise RA, (1994). Place preference conditioning with ventral tegmental injections of cytisine. Life Sci 55: 1179-1186.
45. O'Connor EC, Parker D, Rollema H, Mead AN, (2010). The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-Administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology (Berl) 208: 365-376.
46. Piccari V, Deflorio C, Bigi R, Grassi F, Fucile S, (2011). Modulation of the Ca(2+) permeability of human endplate acetylcholine receptor-channel. Cell Calcium 49: 272-278.
47. Pucci L, Grazioso G, Dallanoce C, Rizzi L, De Micheli C, Clementi F, et al. (2011). Engineering of alpha-conotoxin MII-derived peptides with increased selectivity for native alpha6beta2* nicotinic acetylcholine receptors. FASEB J 25: 3775-3789.
48. Quik M, Wonnacott S, (2011). alpha6beta2* and alpha4beta2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol Rev 63: 938-966.
49. Rasmussen T, Swedberg MD, (1998). Reinforcing effects of nicotinic compounds: intravenous self-Administration in drug-naive mice. Pharmacol Biochem Behav 60: 567-573.
50. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, et al. (2007a). Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52: 985-994.
51. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE, (2007b). Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 28: 316-325.
52. Rollema H, Shrikhande A, Ward KM, Tingley FD 3rd, Coe JW, O'Neill BT, et al. (2010). Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol 160: 334-345.
53. Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC, et al. (2004). Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 65: 1526-1535.
54. Salminen O, Drapeau JA, McIntosh JM, Collins AC, Marks MJ, Grady SR, (2007). Pharmacology of alpha-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice. Mol Pharmacol 71: 1563-1571.
55. Silvia CP, King GR, Lee TH, Xue ZY, Caron MG, Ellinwood EH, (1994). Intranigral administration of D2 dopamine receptor antisense oligodeoxynucleotides establishes a role for nigrostriatal D2 autoreceptors in the motor actions of cocaine. Mol Pharmacol 46: 51-57.
56. Singh S, Loke YK, Spangler JG, Furberg CD, (2011). Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-Analysis. CMAJ 183: 1359-1366.
57. Tutka P, (2008). Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation. Expert Opin Investig Drugs 17: 1473-1485.
58. Wang N, Orr-Urtreger A, Korczyn AD, (2002). The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. Prog Neurobiol 68: 341-360.
59. Watkins SS, Epping-Jordan MP, Koob GF, Markou A, (1999). Blockade of nicotine self-Administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 62: 743-751.
60. Zierler-Brown SL, Kyle JA, (2007). Oral varenicline for smoking cessation. Ann Pharmacother 41: 95-99.